Research Papers:
Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
Metrics: PDF 1569 views | HTML 3175 views | ?
Abstract
Koji Izumi1,2,*, Yusuke Ito1,*, Hiroshi Miyamoto3, Yasuhide Miyoshi4, Junichi Ota2, Masatoshi Moriyama2, Tetsuo Murai5, Hiroyuki Hayashi6, Yoshiaki Inayama7, Kenichi Ohashi8, Masahiro Yao1 and Hiroji Uemura4
1 Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2 Department of Urology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan
3 Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4 Department of Urology, Yokohama City University Medical Center, Yokohama, Japan
5 Department of Urology, International Goodwill Hospital, Yokohama, Japan
6 Department of Pathology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan
7 Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
8 Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
* These authors have contributed equally to this work
Correspondence to:
Koji Izumi, email:
Keywords: bladder cancer, recurrence, androgen receptor, androgen deprivation therapy
Received: November 04, 2015 Accepted: January 29, 2016 Published: February 12, 2016
Abstract
Our recent retrospective study revealed a significantly reduced risk of bladder cancer (BC) recurrence in men who received androgen deprivation therapy (ADT) for their prostate cancer. However, whether androgen receptor (AR) signals contributed to the preventive effect of ADT remained unclear because ADT could reduce serum estrogens as well. The purpose of this study is to investigate the associations between the expression of AR/estrogen receptors (ERs) and BC recurrence in patients treated with ADT. We immunohistochemically stained 72 BCs and 42 corresponding normal urothelial tissues. AR/ERα/ERβ were positive in 44(61%)/22(31%)/39(54%) tumors and 35(83%)/24(57%)/34(81%) corresponding normal urothelial tissues, respectively. There were no statistically significant correlations between AR/ERα/ERβ expression and clinicopathological features of BC. With a median follow-up of 31.3 months, 12 (43%) of 28 patients with AR-negative tumor versus 11 (23%) of 44 patients with AR-positive tumor experienced BC recurrence. Thus, patients with AR-positive tumor had a significantly lower risk of BC recurrence (P=0.031), compared with those with AR-negative tumor. Meanwhile, the expression of ERα/ERβ in tumors and that of AR/ERα/ERβ in normal urothelial tissues were not significantly correlated with BC recurrence. A multivariate analysis revealed AR positivity in tumors as an independent prognosticator (hazard ratio: 0.27; 95% confidence interval: 0.11-0.67) for BC recurrence. These results indicate that ADT prevents BC recurrence via the AR pathway, but not via the ERα/ERβ pathways.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7358